Skin Health & Hair

Overview

Cosmetic peptide research is a mature field — several peptides (GHK-Cu, Matrixyl/palmitoyl pentapeptide, acetyl hexapeptide-3) have decades of research supporting topical use. The distinction here is between well-studied topical applications and more speculative systemic peptide use for skin health.

GHK-Cu (Copper Tripeptide-1) — The Evidence Leader

GHK-Cu is unique in the research peptide space: it has a legitimate, well-documented topical evidence base spanning 50+ years of research.

Documented skin effects:

• Stimulates collagen, elastin, and glycosaminoglycan synthesis by fibroblasts
• Promotes wound healing and skin remodeling
• Reduces inflammatory gene expression
• Upregulates antioxidant enzyme production
• Promotes hair follicle growth in multiple models

Loren Pickart’s research: Pickart identified GHK-Cu in 1973 from human plasma and subsequently documented its ability to modulate over 4,000 genes across skin, liver, and other tissues. This gene-regulatory capacity has been confirmed by independent researchers using modern genomics approaches.

Hair loss: GHK-Cu has been studied for androgenetic alopecia. Animal models and limited human data show follicle stimulation. Often compared favorably to minoxidil in mechanism (though head-to-head human RCT data doesn’t exist).

Forms available:

• Topical serums: Standard cosmetic use; well-established
• Systemic subcutaneous: Research-grade; evidence extrapolated from topical + gene expression data

Peptides Used Systemically for Skin

GH Secretagogues and Skin

Growth hormone has well-documented effects on skin collagen production and thickness. GH-deficient adults have thinner skin; GH restoration improves skin parameters. GH secretagogues (Sermorelin, CJC-1295/Ipamorelin) produce downstream IGF-1 elevation that stimulates fibroblast collagen synthesis.

Limitation: Skin improvement is a secondary endpoint, not the primary studied application. Effects likely exist but are modest compared to GH deficiency treatment.

BPC-157 and Wound Healing

BPC-157’s fibroblast recruitment and angiogenesis effects are mechanistically relevant to wound healing and scar reduction. Some practitioners apply topically to wounds or injection sites (outside standard research protocols).

Distinguishing Cosmetic vs. Medical Claims

The FDA distinguishes cosmetics from drugs: claims of “repairing” or “restructuring” skin tissue cross into drug claim territory. Most GHK-Cu products are marketed as cosmetics (“reduces appearance of wrinkles”) for regulatory reasons — but the underlying mechanism goes well beyond surface appearance.

Evidence Summary

Related Resources

For topical skincare, GHK-Cu at concentrations of 0.5–2% in a serum formulation with appropriate pH is the most evidence-supported approach. See the GHK-Cu encyclopedia entry for concentration and formulation guidance.